Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5381-5391

  Passacantilli, Ilaria ^a,b   Capurso, Gabriele ^b   Archibugi, Livia ^b   Calabretta, Sara ^a,b   Caldarola, Sara ^a   Loreni, Fabrizio ^a   Fave, Gianfranco Delle ^b   Sette, Claudio ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Adaptation to chronic treatment; BEZ235; Combined treatment; MTORC1 chemical inhibitors; PETs; RAD001

Indexed keywords

BLY 719; BUPARLISIB; BYL 719; DACTOLISIB; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, HUMAN; QUINOLINE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; PANCREAS ISLET CELL TUMOR; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; TRANSLATION INITIATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMIDAZOLES; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; QUINOLINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84906238910     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2111     Document Type: Article

References (38)

1. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors. Gastroenterology. 2008; 135(5): 1469-1492.
2. Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ. Changing incidence of pancreatic neoplasms. A 16-year review of statewide tumor registry . Pancreas. 2008; 37(2): 134-8.
3. Panzuto F, Boninsegna L, Fazio N, Campana D, Brizzi MP, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P, Delle Fave G, Falconi M. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis offactors associated with disease progression. J Clin Oncol. 2011; 29(17): 2372-2377.
4. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R; Barcelona Consensus Conferences partecipants. ENET Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012; 95(2): 157-176.
5. Yao JC, Shah MH, Ito T, Lombard Bohas C, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevilla J, de Vires EGE, Tomassetti P, Pavel ME, Hoosen S, Haas T, lincy J, Lebwohl D, et al. Everolimus for Advance Pancreatic Neuroendocrine tumors. N Engl J Med. 2011; 364(6): 514-523.
6. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6): 501-513.
7. Missiaglia E, Dalai I, Barbi S Beghelli S, Falconi M, Della Peruta M, Piemonti L, Capurso G, Di Florio A, Delle Fave G, Pederzoli P, Croce CM, Scarpa A. Pancreatic Endocrine Tumors: Expression profiling evidences a role of PI3K-Akt pathway. J Clin Oncol. 2010; 28(2): 245-255.
8. Jiao Y, Shi C, Edil BH, de Wilde R, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfang CL, Choti MA, Velculescu VE, Diaz Jr LA, Vogelstein B, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011; 331(6021): 1199-1203.
9. Zhou CF, Ji J, Yuan F, Shi M, Zhang J, Liu BY, Zhu ZG. mTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases. Hepato-Gastroenterology, 2011; 58(112): 2140-2143.
10. Di Florio A, Adesso L, Pedrotti S, Capurso G, Pilozzi E, Corbo V, Scarpa A, Geremia R, Delle Fave G, Sette C. Src kinase activity coordinates cell adhesion and spreading with the activation of mammalian target of rapamycin in pancreatic endocrine tumor cells. Endocr Rel Cancer. 2011; 18 (35): 541-554.
11. Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G, Berdondini L, Rea F, Degli Uberti EC. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Rel Cancer. 2010; 17(3): 719-729.
12. Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F, Hervieu V, Gouysse G, Ferraro-Pevret C, Benslama N, Walter T, Scoazec JY, Roche C. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas. Neuroendocrinology. 2013; 97(4): 331-340.
13. Capurso G, Fendrich V, Rinzivillo M, Panzuto F, Bartsch D, Delle Fave G. Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems. Int J Mol Sci. 2013; 14(1): 30-45.
14. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signalling network for cancer therapy. J Clin Oncol. 2009; 27(13): 2278-87.
15. Proud CG. mTORC1 regulates the efficiency and cellular capacity for protein synthesis. Biochem Soc Trans. 2013;41(4):923-926.
16. Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle. 2011; 10(14):2305-2316.
17. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006; 66(3): 1500-1508.
18. Manning BD, Cantely LC. AKT/PKB signalling: navigating downstream. Cell. 2007; 129(7): 1261-1274.
19. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitor with poten in vivo antitumor activity. Mol. Cancer Ther. 2008; 7(7): 1851-1863.
20. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yaun Y, Garcia-Echevrria C, Maira SM, Yung WK. Antitumor activity of NVP-BKM120-A selective Pan Class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res. 2012; 18(1): 184-195.
21. Furet P, Guagnano V, Fairhurst RA, Imbach-weese P, Bruce I, Knapp M, Fritsch C, Blasco F, Blanz J, Aichholz R, Hamon J, Fabbro D, Caravatti G. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 Kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013; 23(13): 3741-3748.
22. Adesso L, Calabretta S, Barbagallo F, Capurso G, Pilozzi E, Geremia R, Delle Fave G, Sette C. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNKs/eiF4E pathway. Oncogene. 2013; 32(23): 2848-2857.
23. Chiang GG, Abraham RT. Phosphorilation of mammalian target of rapamycin (mTOR) at Ser2448 is mediated by p70S6 kinase. J Biol Chem. 2005; 280(27); 25485-25490
24. Laplante M, Sabatini DM. mTOR signalling in growth control and disease. Cell. 2012; 149(2): 274-293.
25. Bianchini A, Loiarro M, Bielli P, Busà R, Paronetto MP, Loreni F, Geremia R, Sette C. (2008) Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis, 29, 2279-2288.
26. Zhang J, Francois R, Iyer R, Seshadri M, Zajac-Kaye M, Hochwald SN. Current understanding of the molecular biology of pancreatic neuroendocrine tumors. J Natl Cancer Inst. 2013; 105(14): 1005-1017.
27. Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F. Everolimus in Advanced Pancreatic Neuroendocrine tumors: the clinical experience. Cancer Res. 2013; 73(5): 1449-1453.
28. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006; 5(8): 671-688.
29. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, Zammit D, Marcus V, Metrakos P, Voyer LA, Gandin V, Liu Y, Topisirovic I, Sonenberg N. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res. 2012; 72(24):6468-6476.
30. Gilley R, Balmanno K, Cope CL, Cook SJ. Adaptation to chronic mTOR inhibition in cancer and aging. Biochem Soc Trans. 2013; 41(4): 956-961.
31. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Active-Site inhibitors of mTOR target rapamycin-resistant Outputs of mTORC1 and mTORC2. PLoS Biol. 2009; 7(2): 371-383.
32. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M,Jessen K, Feldman ME, Weissman JS, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012; 485 (7396): 55-61.
33. Salkeni MA, Rixe O, Karim NA, Ogara S, Feiler M, Moorthy G, Mercer CA, Thomas H, Desai PB, Fathallah H, Kozma S, Thomas G, Morris JC. BEZ235 in combination with everolimus for advanced solid malignancies: Preliminary results of a phase Ib dose-escalation study. J Clin Oncol. 2013; 31 (suppl; abstr e13518).
34. Xie J, Proud CG. Crosstalk between mTOR complexes. Nat Cell Biol. 2013; 15(11):1263-1265.
35. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, Meyuhas O, Shokat KM, Ruggero D. Genetic Dissection of the Oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP1-eIF4E. Cancer Cell. 2010; 17(3): 249-261.
36. Xu CX, Li Y, Yue P, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY. The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against Non-Small cell lung cancer in vitro and in vivo. PLoS One. 2011; 6(6): 1-8.
37. Nyfeler B, Chen Y, Li X, Pinzon-Ortiz M, Wang Z, Reddy A, Pradhan E, Das R, Lehár J, Schlegel R, Finan PM, Cao ZA, Murphy LO, Huang A. RAD001 enhances the potency of BEZ235 to inhibit mTOR signalling and tumor growth. PLoS One. 2012; 7(11): 1-9.
38. Di Florio A, Capurso G, Milione M, Panzuto F, Geremia R, Delle Fave G, Sette C. Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumor cells. End Relat Cancer. 2007; 14(1): 111-124.